DE69430317D1 - Wasserlösliche aktive sulfone von polyethylenglycolen - Google Patents

Wasserlösliche aktive sulfone von polyethylenglycolen

Info

Publication number
DE69430317D1
DE69430317D1 DE69430317T DE69430317T DE69430317D1 DE 69430317 D1 DE69430317 D1 DE 69430317D1 DE 69430317 T DE69430317 T DE 69430317T DE 69430317 T DE69430317 T DE 69430317T DE 69430317 D1 DE69430317 D1 DE 69430317D1
Authority
DE
Germany
Prior art keywords
peg
substances
water
soluble active
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430317T
Other languages
English (en)
Other versions
DE69430317T2 (de
Inventor
Milton Harris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shearwater Corp filed Critical Shearwater Corp
Publication of DE69430317D1 publication Critical patent/DE69430317D1/de
Application granted granted Critical
Publication of DE69430317T2 publication Critical patent/DE69430317T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/321Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/326Polymers modified by chemical after-treatment with inorganic compounds containing sulfur
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent
DE69430317T 1993-11-12 1994-11-14 Wasserlösliche aktive sulfone von polyethylenglycolen Expired - Lifetime DE69430317T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/151,481 US5446090A (en) 1993-11-12 1993-11-12 Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
PCT/US1994/013013 WO1995013312A1 (en) 1993-11-12 1994-11-14 Water soluble active sulfones of poly(ethylene glycol)

Publications (2)

Publication Number Publication Date
DE69430317D1 true DE69430317D1 (de) 2002-05-08
DE69430317T2 DE69430317T2 (de) 2002-10-02

Family

ID=22538958

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430317T Expired - Lifetime DE69430317T2 (de) 1993-11-12 1994-11-14 Wasserlösliche aktive sulfone von polyethylenglycolen

Country Status (26)

Country Link
US (6) US5446090A (de)
EP (2) EP1176160A3 (de)
JP (1) JP3114998B2 (de)
KR (1) KR100225746B1 (de)
CN (1) CN1085689C (de)
AT (1) ATE215577T1 (de)
AU (1) AU687937B2 (de)
BG (1) BG63399B1 (de)
BR (1) BR9408048A (de)
CA (1) CA2176203C (de)
CZ (1) CZ295640B6 (de)
DE (1) DE69430317T2 (de)
DK (1) DK0728155T3 (de)
EE (1) EE03448B1 (de)
ES (1) ES2173943T3 (de)
FI (1) FI117441B (de)
HK (1) HK1042312A1 (de)
HU (1) HU225649B1 (de)
NO (1) NO315377B1 (de)
NZ (1) NZ276313A (de)
PL (1) PL180149B1 (de)
RO (2) RO118434B1 (de)
RU (1) RU2176253C2 (de)
SK (1) SK284527B6 (de)
UA (1) UA58481C2 (de)
WO (1) WO1995013312A1 (de)

Families Citing this family (440)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6552170B1 (en) * 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
NZ503548A (en) 1996-02-09 2001-09-28 Amgen Inc A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
US5747639A (en) * 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998012274A1 (en) * 1996-09-23 1998-03-26 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US8003705B2 (en) * 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6072040A (en) * 1996-10-15 2000-06-06 Medical Analysis Systems, Inc. Stabilized conjugates of uncomplexed subunits of multimeric proteins
DE69724451T2 (de) 1996-12-06 2004-03-18 Amgen Inc., Thousand Oaks Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6743248B2 (en) 1996-12-18 2004-06-01 Neomend, Inc. Pretreatment method for enhancing tissue adhesion
US20030191496A1 (en) * 1997-03-12 2003-10-09 Neomend, Inc. Vascular sealing device with microwave antenna
US6371975B2 (en) 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US20040176801A1 (en) * 1997-03-12 2004-09-09 Neomend, Inc. Pretreatment method for enhancing tissue adhesion
WO1998051336A1 (en) * 1997-05-15 1998-11-19 Theratech, Inc. Targeted delivery to t lymphocytes
US6284246B1 (en) 1997-07-30 2001-09-04 The Procter & Gamble Co. Modified polypeptides with high activity and reduced allergenicity
US6251866B1 (en) 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor
US6168784B1 (en) 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use
US6129928A (en) * 1997-09-05 2000-10-10 Icet, Inc. Biomimetic calcium phosphate implant coatings and methods for making the same
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
EP1061954B1 (de) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Polyethylenglycolderivate mit benachbarten reaktiven gruppen
US6066673A (en) * 1998-03-12 2000-05-23 The Procter & Gamble Company Enzyme inhibitors
US6495136B1 (en) 1998-03-26 2002-12-17 The Procter & Gamble Company Proteases having modified amino acid sequences conjugated to addition moieties
JP2002507426A (ja) 1998-03-26 2002-03-12 ザ、プロクター、エンド、ギャンブル、カンパニー アミノ酸置換を有するセリンプロテアーゼ変異体
US6908757B1 (en) 1998-03-26 2005-06-21 The Procter & Gamble Company Serine protease variants having amino acid deletions and substitutions
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6994686B2 (en) * 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
US6458147B1 (en) 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
JP2002528562A (ja) 1998-08-28 2002-09-03 グリフォン サイエンシーズ 長さのばらつきが小さいポリアミド連鎖、その連鎖の製造方法およびその連鎖とタンパク質の複合体
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
WO2000016733A2 (en) 1998-09-22 2000-03-30 The Procter & Gamble Company Personal care compositions containing active proteins tethered to a water insoluble substrate
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6949114B2 (en) 1998-11-06 2005-09-27 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US7279001B2 (en) * 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6899889B1 (en) * 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US6830756B2 (en) * 1998-11-06 2004-12-14 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
WO2000033764A1 (en) * 1998-12-04 2000-06-15 Pathak Chandrashekhar P Biocompatible crosslinked polymers
US6958212B1 (en) * 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
AU773914B2 (en) 1999-02-01 2004-06-10 Eidgenossische Technische Hochschule Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
WO2000078285A1 (en) * 1999-06-18 2000-12-28 University Of Medicine And Dentistry Of New Jersey Controlled release of therapeutics by in-situ entrapment by matrix cross-linking
KR20020021397A (ko) 1999-07-22 2002-03-20 데이비드 엠 모이어 규정된 에피토프 영역에 아미노산 결실 및 치환을 갖는서브틸리신 프로테아제 변이체
AU5928400A (en) 1999-07-22 2001-02-13 Procter & Gamble Company, The Protease conjugates having sterically protected clip sites
US6946128B1 (en) 1999-07-22 2005-09-20 The Procter & Gamble Company Protease conjugates having sterically protected epitope regions
CN1399677A (zh) 1999-07-22 2003-02-26 宝洁公司 在确定表位区有氨基酸取代的枯草杆菌蛋白酶变体
US7008635B1 (en) 1999-09-10 2006-03-07 Genzyme Corporation Hydrogels for orthopedic repair
US6303119B1 (en) 1999-09-22 2001-10-16 The Procter & Gamble Company Personal care compositions containing subtilisin enzymes bound to water insoluble substrates
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
DK1257295T3 (da) 2000-02-11 2009-08-10 Bayer Healthcare Llc Faktor VII eller VIIA-lignende molekyler
JP2003533681A (ja) 2000-05-15 2003-11-11 テカン・トレーディング・アクチェンゲゼルシャフト ミクロ流体装置および細胞ベースの分析を実行する方法
ATE367398T1 (de) * 2000-05-16 2007-08-15 Bolder Biotechnology Inc Verfahren zur rückfaltung von proteinen mit freien cysteinresten
US7291673B2 (en) * 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
KR20030036591A (ko) * 2000-07-12 2003-05-09 그리폰 테라퓨틱스, 인코포레이티드 폴리머-변형 생물활성 합성 키모카인, 및 그것의 제조와사용방법
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
WO2002019963A2 (en) * 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
AU2002245205B2 (en) * 2000-10-19 2007-07-19 Ecole Polytechnique Federale De Lausanne Block copolymers for multifunctional self-assembled systems
ATE537845T1 (de) 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
US7053150B2 (en) * 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
EP1366075B1 (de) 2001-02-27 2009-05-27 Maxygen Aps Neue interferon-beta-ähnliche moleküle
MXPA03008498A (es) * 2001-03-20 2005-06-30 Univ Zuerich Procesamiento en dos fases de polimeros termosensibles para uso como biomateriales.
US6538104B2 (en) * 2001-04-27 2003-03-25 Medical Analysis Systems, Inc. Stabilization of cardiac troponin I subunits and complexes
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
DE60223047T2 (de) * 2001-08-22 2008-07-24 Bioartificial Gel Technologies Inc., Montreal Verfahren zur herstellung von aktivierten polyethylenglykolen
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
EP2298354B1 (de) 2001-10-10 2014-03-19 ratiopharm GmbH Neumodulierung und Glykokonjugation von Interferon-beta
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
CN101724075B (zh) 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
DK2939696T3 (en) 2001-10-18 2016-05-23 Nektar Therapeutics Polymer Conjugates of Opioid Antagonists
US8013134B2 (en) * 2001-11-23 2011-09-06 Olink Ab Kit for proximity probing with multivalent proximity probes
PL213322B1 (pl) 2002-01-18 2013-02-28 Biogen Idec Inc Kompozycja farmaceutyczna zawierajaca polimer glikolu polialkilenowego skoniugowany z biologicznie aktywnym zwiazkiem lub jego prekursorem oraz jej zastosowania
US20030179692A1 (en) * 2002-03-19 2003-09-25 Yoshitaka Ohotomo Storage medium
US8282912B2 (en) * 2002-03-22 2012-10-09 Kuros Biosurgery, AG Compositions for tissue augmentation
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CN101301475B (zh) 2002-06-21 2012-12-19 诺和诺德医疗保健公司 Peg化因子vii糖型
MXPA04012496A (es) 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
US7034127B2 (en) * 2002-07-02 2006-04-25 Genzyme Corporation Hydrophilic biopolymer-drug conjugates, their preparation and use
AU2003270341A1 (en) * 2002-09-05 2004-03-29 The General Hospital Corporation Modified asialo-interferons and uses thereof
US20040136956A1 (en) * 2002-09-05 2004-07-15 Barker Nicholas P. Asialo-interferons and the treatment of liver cancer
WO2004022629A2 (en) * 2002-09-09 2004-03-18 Nektar Therapeutics Al, Corporation Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
CN1312279C (zh) * 2002-11-07 2007-04-25 连云港新阳医药有限公司 聚乙二醇修饰门冬酰胺酶的制备方法
EP1667708B9 (de) * 2002-12-26 2012-10-31 Mountain View Pharmaceuticals, Inc. INTERFERON-BETA-1b POLYETHYLENEGLYKOL-KONJUGATE MIT ERHÖHTER IN VITRO BIOLOGISCHER WIRKSAMKEIT
EA013535B1 (ru) * 2002-12-26 2010-06-30 Маунтин Вью Фамэсьютикэлс, Инк. Полимерный конъюгат биоактивного компонента (варианты), способ его получения и использования, фармацевтические продукты на его основе
EP1616003A4 (de) * 2002-12-30 2007-06-20 Gryphon Therapeutics Inc Wasserlösliche thioester- und selenoesterverbindungen sowie verfahren zur herstellung und verwendung davon
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
CN1723232B (zh) * 2003-01-06 2012-08-22 尼克塔治疗公司 巯基选择性水溶性聚合物衍生物
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
JP4490413B2 (ja) 2003-01-06 2010-06-23 ネクター セラピューティクス アラバマ,コーポレイション チオール選択的水溶性ポリマー誘導体
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
EP2572732A1 (de) 2003-02-26 2013-03-27 Nektar Therapeutics Konjugate mit Polymer-Faktor-VIII-Anteil
US20090123367A1 (en) * 2003-03-05 2009-05-14 Delfmems Soluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
EP2405015B1 (de) * 2003-03-05 2016-01-06 Halozyme, Inc. Lösliches Hyaluronidaseglykoprotein (sHASEGP), Verfahren zu dessen Herstellung, Verwendungen und pharmazeutische Zusammensetzungen, die dieses umfassen
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
US7610156B2 (en) * 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7587286B2 (en) * 2003-03-31 2009-09-08 Xencor, Inc. Methods for rational pegylation of proteins
US7642340B2 (en) 2003-03-31 2010-01-05 Xencor, Inc. PEGylated TNF-α variant proteins
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
DK2599502T3 (en) 2003-04-11 2017-04-18 Antriabio Inc Process for Preparation of Site-Specific Protein Conjugates
JP4753867B2 (ja) 2003-04-15 2011-08-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー ヒトil−18を含むコンジュゲートおよびその置換変異体
BRPI0410164A (pt) 2003-05-09 2006-05-16 Neose Technologies Inc composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
AU2004259327B2 (en) 2003-07-22 2009-12-17 Nektar Therapeutics Method for preparing functionalized polymers from polymer alcohols
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
DK1663281T3 (en) * 2003-08-29 2014-03-17 Dyax Corp POLY-PEGYLED PROTEASE INHIBITORS
KR20120073370A (ko) 2003-09-17 2012-07-04 넥타르 테라퓨틱스 다분지형 고분자 전구약물
SG143252A1 (en) * 2003-10-09 2008-06-27 Ambrx Inc Polymer derivatives
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
CA2542179A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
ES2428358T3 (es) * 2003-10-17 2013-11-07 Novo Nordisk A/S Terapia de combinación
EP1725572B1 (de) 2003-11-05 2017-05-31 AGCT GmbH Makromolekulare nukleotidverbindungen und methoden zu deren anwendung
US20070254834A1 (en) * 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
CN1925843A (zh) 2003-12-02 2007-03-07 细胞免疫科学公司 生产单克隆抗体的方法和组合物
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
AU2005209318B2 (en) * 2004-01-28 2010-02-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
NZ586034A (en) * 2004-02-02 2011-10-28 Ambrx Inc Modified human growth hormone polypeptides and their uses
KR100580644B1 (ko) * 2004-02-16 2006-05-16 삼성전자주식회사 생물분자를 고체 기판상에 비공유적으로 고정화 하는 방법및 그에 의하여 제조되는 마이크로어레이
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
CN101132812A (zh) * 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
EP1735340A2 (de) * 2004-03-17 2006-12-27 Eli Lilly And Company Glykolgebundene fgf-21-verbindungen
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1773375A1 (de) 2004-07-14 2007-04-18 University of Utah Research Foundation Netrin-verwandte zusammensetzungen und anwendungen
BRPI0512396A (pt) * 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
EP1799249A2 (de) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CA2584510C (en) * 2004-10-25 2013-05-28 Intezyne Technologies, Incorporated Heterobifunctional poly(ethylene glycol) and uses thereof
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
ES2357089T5 (es) 2004-12-21 2014-02-24 Nektar Therapeutics Reactivos de tiol polimérico estabilizados
KR101224781B1 (ko) * 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
JP2008525032A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 組換えヒト成長ホルモンを発現及び精製するための方法
US7736872B2 (en) * 2004-12-22 2010-06-15 Ambrx, Inc. Compositions of aminoacyl-TRNA synthetase and uses thereof
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
CA2594557C (en) * 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
EP1858543B1 (de) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
EP1846505B1 (de) * 2005-02-09 2015-11-11 Covidien LP Synthetische dichtungsmittel
US20100092505A1 (en) 2005-04-05 2010-04-15 Elisabetta Bianchi Method for Shielding Functional Sites or Epitopes on Proteins
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8273339B2 (en) * 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
JP2008538290A (ja) 2005-04-18 2008-10-23 ノボ ノルディスク アクティーゼルスカブ Il−21変異体
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US8183340B2 (en) 2005-05-13 2012-05-22 Eli Lilly And Company GLP-1 pegylated compounds
US20080255026A1 (en) * 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2007008300A2 (en) * 2005-05-31 2007-01-18 ECOLE POLYTECHNIQUE FéDéRALE DE LAUSANNE Triblock copolymers for cytoplasmic delivery of gene-based drugs
JP2008541769A (ja) * 2005-06-03 2008-11-27 アンブレツクス・インコーポレイテツド 改善されたヒトインターフェロン分子及びそれらの使用
NZ564222A (en) 2005-06-14 2011-10-28 Taigen Biotechnology Co Ltd Pyrimidine compounds
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP2412744B1 (de) 2005-07-18 2014-01-22 Nektar Therapeutics Verfahren zur Herstellung von verzweigten funktionalisierten Polymeren mithilfe von verzweigten Polyol-Kernen
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP4829969B2 (ja) * 2005-08-18 2011-12-07 アンブルックス,インコーポレイテッド tRNA組成物、およびその使用
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
WO2007056448A2 (en) * 2005-11-08 2007-05-18 Ambrx, Inc. Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CN101454461A (zh) * 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
JP2009519942A (ja) * 2005-12-14 2009-05-21 アンブルックス,インコーポレイテッド 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
US7743730B2 (en) * 2005-12-21 2010-06-29 Lam Research Corporation Apparatus for an optimized plasma chamber grounded electrode assembly
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
EP1984009B1 (de) * 2006-01-18 2012-10-24 Qps, Llc Pharmazeutische zusammensetzungen mit verbesserter stabilität
US8309680B2 (en) 2006-02-21 2012-11-13 Nektar Therapeutics Segmented degradable polymers and conjugates made therefrom
EP2004231A4 (de) 2006-04-07 2013-07-10 Nektar Therapeutics Konjugate eines anti-tnf-alpha-antikörpers
CA2648936C (en) 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
WO2007127473A2 (en) 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
RU2008145084A (ru) 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
JP2009541333A (ja) 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
WO2008002482A2 (en) * 2006-06-23 2008-01-03 Surmodics, Inc. Hydrogel-based joint repair system and method
JP2009543868A (ja) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
JP5840345B2 (ja) * 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
DK2061878T3 (da) * 2006-09-08 2014-04-07 Ambrx Inc Hybridsuppressor-trna for hvirveldyrceller
MX2009002526A (es) * 2006-09-08 2009-04-16 Ambrx Inc Transcripcion de tarn supresor en celulas de vertebrados.
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CA2665480C (en) * 2006-10-04 2019-11-12 Shawn Defrees Glycerol linked pegylated sugars and glycopeptides
AR063384A1 (es) * 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
EP2091968A2 (de) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21-varianten
EP3156415A1 (de) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Gezielte therapeutik auf grundlage manipulierter proteine für tyrosinkinaserezeptoren, einschliesslich igf-ir
JP5277417B2 (ja) 2006-11-30 2013-08-28 ネクター セラピューティクス ポリマー複合体を調製する方法
DK2121751T3 (en) 2006-12-08 2017-04-24 Lexicon Pharmaceuticals Inc Monoclonal antibodies to ANGPTL3
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
WO2008075192A2 (en) * 2006-12-19 2008-06-26 Bracco International Bv Targeting and therapeutic compounds and gas-filled microvesicles comprising said com ounds
US8685417B2 (en) 2006-12-20 2014-04-01 Arkema, Inc. Polymer encapsulation and/or binding
UA95996C2 (ru) 2007-01-18 2011-09-26 Эли Лилли Энд Компани Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
KR101476472B1 (ko) * 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 fgf-21 폴리펩티드 및 그 용도
DK2144923T3 (da) 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
EP2537539B1 (de) * 2007-04-13 2019-04-03 Kuros Biosurgery AG Polymergewebeversiegelungsmittel
NZ580686A (en) * 2007-05-02 2012-11-30 Ambrx Inc Modified interferon beta polypeptides and their uses
EP2162540A2 (de) 2007-05-22 2010-03-17 Amgen Inc. Zusammensetzungen und verfahren zur herstellung biologisch aktiver fusionsproteine
ES2551123T3 (es) 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术(上海)有限公司 白介素-22在治疗脂肪肝中的应用
US20110269942A1 (en) * 2007-08-09 2011-11-03 Daiichi Sankyo Company, Limited Antibodies modified with hydrophobic molecule
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2200932A4 (de) * 2007-09-21 2014-09-10 Cytimmune Sciences Inc Nanotherapeutische kolloidale metallzusammensetzungen und verfahren
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
EP2205271B1 (de) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Zusammensetzungen und verfahren für therapien auf ribonukleasebasis
CN101835496B (zh) * 2007-10-23 2015-11-25 尼克塔治疗公司 靶向羟基磷灰石的多臂聚合物以及由其制造的偶联物
EP2219458B1 (de) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Zusammensetzungen und verfahren für die erzeugung von antikörpern
US20090123519A1 (en) * 2007-11-12 2009-05-14 Surmodics, Inc. Swellable hydrogel matrix and methods
EP2209834B1 (de) * 2007-11-12 2011-06-08 Intradigm Corporation Heterobifunktionelle polyethylenglycol-reagenzien
AU2008326324B9 (en) * 2007-11-20 2012-11-15 Ambrx, Inc. Modified insulin polypeptides and their uses
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20090226531A1 (en) * 2008-03-07 2009-09-10 Allergan, Inc. Methods and composition for intraocular delivery of therapeutic sirna
KR101647932B1 (ko) 2008-04-14 2016-08-11 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
EP2268635B1 (de) 2008-04-21 2015-06-10 Taigen Biotechnology Co., Ltd. Heterocyclische verbindungen
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
CA2723821C (en) * 2008-05-16 2017-05-02 Nektar Therapeutics Conjugates of a cholinesterase moiety and a polymer
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
EP2326349B1 (de) * 2008-07-21 2015-02-25 Polytherics Limited Neue reagenzien und verfahren zur konjugation von biologischen molekülen
ES2963062T3 (es) * 2008-07-23 2024-03-25 Ambrx Inc Polipéptidos G-CSF bovinos modificados y sus usos
CA2732508C (en) 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
EP2334336A1 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von osteocalcin-peptiden
EP2344200A2 (de) * 2008-09-19 2011-07-20 Nektar Therapeutics Modifizierte therapeutische peptide, herstellungsverfahren und verwendung
EP2344199A1 (de) * 2008-09-19 2011-07-20 Nektar Therapeutics Polymer-konjugate von thymosin-alpha1-peptiden
WO2010033223A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of opioid growth factor peptides
US20110165113A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of v681-like peptides
EP2334338A2 (de) * 2008-09-19 2011-06-22 Nektar Therapeutics Polymerkonjugate von c-peptiden
US20110237524A1 (en) * 2008-09-19 2011-09-29 Nektar Therapeutics Polymer conjugates of aod-like peptides
CA2737040C (en) 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2337585A1 (de) * 2008-09-19 2011-06-29 Nektar Therapeutics Polymerkonjugate von glp-2-artigen peptiden
WO2010033222A2 (en) * 2008-09-19 2010-03-25 Netkar Therapeutics Polymer conjugates of ziconotide peptides
WO2010033221A1 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of protegrin peptides
US20110171160A1 (en) * 2008-09-19 2011-07-14 Nektar Therapeutics Polymer conjugates of kiss1 peptides
US20110206633A1 (en) * 2008-09-19 2011-08-25 Nektar Therapectics Polymer conjugates of cd-np peptides
BRPI0919403A2 (pt) 2008-09-26 2017-09-26 Ambrx Inc polipeptídeos modificados de eritropoetina animal e seus usos
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
EP2334695B1 (de) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutische ribonukleasen
WO2010056847A2 (en) 2008-11-13 2010-05-20 Taigen Biotechnology Co., Ltd. Lyophilization formulation
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
PT3037529T (pt) 2008-12-09 2019-05-31 Halozyme Inc Polipéptidos ph20 estendidos solúveis e suas utilizações
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
WO2010080720A2 (en) 2009-01-12 2010-07-15 Nektar Therapeutics Conjugates of a lysosomal enzyme moiety and a water soluble polymer
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
TWI626057B (zh) 2009-06-09 2018-06-11 普龍製藥有限責任公司 血紅素組成物
RU2012107812A (ru) 2009-08-05 2013-09-10 Аллерган, Инк. Препараты мутеинов липокалинов с контролируемым высвобождением
DK2477603T3 (en) 2009-09-17 2016-06-13 Baxalta Inc STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF
US9315860B2 (en) 2009-10-26 2016-04-19 Genovoxx Gmbh Conjugates of nucleotides and method for the application thereof
AU2010313456A1 (en) 2009-10-30 2012-05-17 Ntf Therapeutics, Inc. Improved neurturin molecules
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
ES2688093T3 (es) 2010-01-06 2018-10-30 Dyax Corp. Proteínas de unión a calicreína plasmática
CN102161754B (zh) * 2010-02-13 2012-06-13 华中科技大学同济医学院附属协和医院 枝化状聚乙二醇衍生物的功能化修饰方法
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
EP2563380B1 (de) 2010-04-26 2018-05-30 aTyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten der cysteinyl-trna-synthetase
AU2011248614B2 (en) 2010-04-27 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
US8993723B2 (en) 2010-04-28 2015-03-31 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl-tRNA synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (de) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von valyl-trna-synthetasen
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
ES2623805T3 (es) 2010-05-03 2017-07-12 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de fenilalanil-alfa-ARNt sintetasas
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ, インコーポレイテッド p38MULTI−tRNA合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Vla4のポリペプチド阻害剤
AU2011252990B2 (en) 2010-05-14 2017-04-20 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
JP2013533217A (ja) 2010-05-17 2013-08-22 セビックス・インコーポレイテッド Peg化c−ペプチド
CA2799480C (en) 2010-05-17 2020-12-15 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
EP2575856B1 (de) 2010-05-27 2017-08-16 aTyr Pharma, Inc. Therapeutische, diagnostische und antikörperhaltige zusammensetzungen in zusammenhang mit proteinfragmenten von glutaminyl-trna-synthetasen
WO2011153277A2 (en) 2010-06-01 2011-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
WO2012021247A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
ES2661089T3 (es) 2010-07-20 2018-03-27 Halozyme Inc. Métodos de tratamiento o prevención de los efectos secundarios adversos asociados con la administración de un agente anti-hialuronano
KR102411923B1 (ko) 2010-07-30 2022-06-22 알콘 인코포레이티드 수분이 풍부한 표면을 갖는 실리콘 히드로겔 렌즈
EP2605789B1 (de) 2010-08-17 2019-06-05 Ambrx, Inc. Modifizierte relaxinpolypeptide und ihre verwendungen
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
WO2012054822A1 (en) 2010-10-22 2012-04-26 Nektar Therapeutics Pharmacologically active polymer-glp-1 conjugates
EA037083B1 (ru) 2010-11-12 2021-02-03 Нектар Терапьютикс Иммуномодулирующий конъюгат, включающий il-2 и водорастворимые полимеры
CA2817568A1 (en) 2010-11-12 2012-05-18 The Salk Institute For Biological Studies Intellectual Property And Tech Nology Transfer Cancer therapies and diagnostics
MX357166B (es) 2010-11-24 2018-06-28 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
US20140371258A1 (en) 2010-12-17 2014-12-18 Nektar Therapeutics Water-Soluble Polymer Conjugates of Topotecan
JP5899241B2 (ja) 2010-12-21 2016-04-06 ネクター セラピューティクス ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EP2661450A4 (de) 2011-01-06 2014-04-23 Dyax Corp Plasmakallikreinbindende proteine
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
EP2686340A2 (de) 2011-03-16 2014-01-22 Amgen Inc. Hochwirksame und selektive inhibitoren von nav1.3 nav1.7
EP2709669A1 (de) 2011-05-17 2014-03-26 Bristol-Myers Squibb Company Verfahren zur aufrechterhaltung der pegylierung von polypeptiden
WO2012166555A1 (en) 2011-05-27 2012-12-06 Nektar Therapeutics Water - soluble polymer - linked binding moiety and drug compounds
CN103687622A (zh) 2011-06-16 2014-03-26 香港科技大学 含有多个乙烯砜的分子
WO2012174480A2 (en) 2011-06-17 2012-12-20 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US20130011378A1 (en) 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme
MX340172B (es) 2011-06-17 2016-06-28 Halozyme Inc Formulaciones estables de una enzima degradadora de hialuronano.
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
WO2013020079A2 (en) 2011-08-04 2013-02-07 Nektar Therapeutics Conjugates of an il-11 moiety and a polymer
WO2013040501A1 (en) 2011-09-16 2013-03-21 Pharmathene, Inc. Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
BR112014009797A2 (pt) 2011-10-24 2020-10-27 Halozyme, Inc. diagnóstico de companhia para terapia de agente anti-hialuronano e métodos de uso do mesmo
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 低減した免疫原性を有するフィブロネクチン結合ドメイン
CA2855770A1 (en) 2011-11-17 2013-05-23 Cebix Ab Pegylated c-peptide
WO2013086015A1 (en) 2011-12-05 2013-06-13 Incept, Llc Medical organogel processes and compositions
US10077290B2 (en) 2011-12-29 2018-09-18 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
PT3130347T (pt) 2011-12-30 2019-12-10 Halozyme Inc Variantes de polipéptidos de ph20, suas formulações e utilizações
EP2814514B1 (de) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna-synthetasen zur behandlung von autoimmun- und entzündungserkrankungen
BR112014024291B1 (pt) 2012-03-30 2022-07-05 The Board Of Regents Of The University Of Oklahoma Método para a produção de forma recombinante de um polímero de heparosan com alto peso molecular, uso do referido polímero para aumento de tecido, polinucleotídeo isolado e composição de material biológico compreendendo o referido polímero
US8956682B2 (en) 2012-04-02 2015-02-17 Surmodics, Inc. Hydrophilic polymeric coatings for medical articles with visualization moiety
CA2986512C (en) 2012-04-04 2022-05-17 Halozyme, Inc. Combination therapy with an anti-hyaluronan agent and a tumor-targeted taxane
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. c−Metに結合する抗原結合タンパク質
JP6438391B2 (ja) 2012-06-22 2018-12-12 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. Ccr2に結合する抗原結合タンパク質
EP2863955B1 (de) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
US9932565B2 (en) 2012-07-31 2018-04-03 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
SI3584255T1 (sl) 2012-08-31 2022-05-31 Sutro Biopharma, Inc Modificirane aminokisline, ki vsebujejo azido skupino
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2916835A4 (de) 2012-11-12 2016-07-27 Redwood Bioscience Inc Verbindungen und verfahren zur herstellung eines konjugats
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
KR20150085064A (ko) 2012-11-16 2015-07-22 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 단백질 화학적 변형을 위한 피크테 스펭글러 결합
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
EP2935311B1 (de) 2012-12-20 2021-03-31 Amgen Inc. Apj-rezeptoragonisten und verwendungen davon
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
US10308926B2 (en) 2013-03-15 2019-06-04 Dana-Farber Cancer Institute, Inc. Stablized EZH2 peptides
AU2014227824B2 (en) 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
CA2906775A1 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ph20玻尿酸酶變異體及其用途
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3069195B8 (de) 2013-11-15 2019-07-10 Tangible Science, LLC Kontaktlinse mit hydrophiler schicht
CA2927806C (en) 2013-11-27 2023-01-10 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
KR102555955B1 (ko) 2014-03-27 2023-07-18 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
MA39711A (fr) 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
JP7059003B2 (ja) 2014-05-14 2022-04-25 トラスティーズ・オブ・ダートマス・カレッジ 脱免疫化リゾスタフィン及び使用方法
WO2015191781A2 (en) 2014-06-10 2015-12-17 Amgen Inc. Apelin polypeptides
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JP6800141B2 (ja) 2014-08-12 2020-12-16 マサチューセッツ インスティテュート オブ テクノロジー Il−2およびインテグリン結合性fc融合タンパク質による相乗的な腫瘍処置
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
WO2016033555A1 (en) 2014-08-28 2016-03-03 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
JP6625627B2 (ja) 2014-10-14 2019-12-25 ハロザイム インコーポレイテッド アデノシンデアミナーゼ−2(ada2)、その変異体の組成物およびそれを使用する方法
WO2016059377A1 (en) * 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
CN107073131B (zh) * 2014-10-24 2021-05-25 宝力泰锐克斯有限公司 缀合物和缀合试剂
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
JP6774947B2 (ja) * 2014-12-09 2020-10-28 タンジブル サイエンス インコーポレイテッド 生体適合性層を有する医療デバイスコーティング
CA2979999A1 (en) 2015-03-18 2016-09-22 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
EP3317294B1 (de) 2015-07-02 2023-03-15 Dana-Farber Cancer Institute, Inc. Stabilisierte antimikrobielle peptide
JP7049989B2 (ja) 2015-08-28 2022-04-07 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド Bfl-1と結合するペプチド
CA2994447A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP6883590B2 (ja) 2016-01-29 2021-06-09 ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. Pd−l1に結合する抗原結合性タンパク質
AU2017228333C1 (en) 2016-02-29 2022-03-10 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
US10421785B2 (en) 2016-04-11 2019-09-24 Bar-Ilan University Delta receptor agonist peptides and use thereof
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
EP3503924B1 (de) 2016-08-26 2022-12-14 Dana-Farber Cancer Institute, Inc. Bcl-w-polypeptide und mimetika zur behandlung oder prävention von chemotherapieinduzierter peripherer neuropathie und hörverlust
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
WO2018172503A2 (en) 2017-03-24 2018-09-27 Basf Se Liquid laundry detergent comprising modified saccharide or polysaccharide
SG11201912071QA (en) 2017-06-22 2020-01-30 Catalyst Biosciences Inc Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
AU2018304230A1 (en) 2017-07-19 2020-02-06 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides for the treatment of antibiotic-resistant bacterial infections
WO2019036605A2 (en) 2017-08-17 2019-02-21 Massachusetts Institute Of Technology MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
EP3688007A1 (de) 2017-09-27 2020-08-05 The University of York Biokonjugation von polypeptiden
CA3078682A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
JP2021506800A (ja) 2017-12-15 2021-02-22 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 構造安定化および/またはシステイン反応性noxaペプチドによるアポトーシスタンパク質の選択的標的化
EP3732254A4 (de) 2017-12-26 2021-12-22 Becton, Dickinson and Company Tiefe uv-erregbare wassersolvatisierte polymerfarbstoffe
CA3089279A1 (en) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
WO2019178313A1 (en) 2018-03-14 2019-09-19 Dana-Farber Cancer Institute, Inc. Stabilized peptides for biomarker detection
US10844228B2 (en) 2018-03-30 2020-11-24 Becton, Dickinson And Company Water-soluble polymeric dyes having pendant chromophores
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
CA3107332A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies Inc. Treatment of lymphatic metastases
CA3110647A1 (en) 2018-08-28 2020-03-05 Ambrx, Inc. Anti-cd3 antibody folate bioconjugates and their uses
SG11202102427XA (en) 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
EP3852783A1 (de) 2018-09-17 2021-07-28 Massachusetts Institute of Technology Für proteine der bcl-2-familie selektive peptide
EP3867265A1 (de) 2018-10-19 2021-08-25 Ambrx, Inc. Interleukin-10 -polypeptid-konjugate, dimere davon und ihre verwendungen
US20200262887A1 (en) 2018-11-30 2020-08-20 Opko Ireland Global Holdings, Ltd. Oxyntomodulin peptide analog formulations
WO2020131871A1 (en) * 2018-12-19 2020-06-25 Tangible Science, Inc. Systems and methods of treating a hydrogel-coated medical device
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
CA3176021A1 (en) 2018-12-28 2020-07-02 Catalyst Biosciences, Inc. Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3914289A1 (de) 2019-01-23 2021-12-01 Massachusetts Institute of Technology Dosierungsschema einer kombinationsimmunotherapie für immunprüfpunktblockade
JP2022520792A (ja) 2019-02-12 2022-04-01 アンブルックス,インコーポレイテッド 抗体-tlrアゴニストコンジュゲートを含有する組成物、その方法、及び使用
US20220169688A1 (en) 2019-04-18 2022-06-02 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
EP3958983A1 (de) 2019-04-26 2022-03-02 The Procter & Gamble Company Reduktion von zahnverfärbung aus kationischen antimikrobiellen mitteln
EP4077361A1 (de) 2019-12-16 2022-10-26 Dana-Farber Cancer Institute, Inc. Strukturstabilisierte oncolytische peptide und verwendungen davon
WO2021127493A1 (en) 2019-12-20 2021-06-24 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
EP4090674A4 (de) 2020-01-14 2024-01-24 Synthekine Inc Vorgespannte il2-muteins-verfahren und -zusammensetzungen
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
WO2021178714A2 (en) 2020-03-04 2021-09-10 Dana-Farber Cancer Institute, Inc. ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of using them
EP4139360A1 (de) 2020-04-22 2023-03-01 Dana-Farber Cancer Institute, Inc. Antivirale strukturell stabilisierte ace2-helix-1-peptide und verwendungen davon
CA3179873A1 (en) 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
WO2022040596A1 (en) 2020-08-20 2022-02-24 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US20230330238A1 (en) 2020-10-14 2023-10-19 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
EP4240395A1 (de) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antivirale strukturell stabilisierte ebolaviruspeptide und verwendungen davon
IL307282A (en) 2021-04-03 2023-11-01 Ambrx Inc Antidote conjugates against HER2 and their applications
AU2022341116A1 (en) 2021-09-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
EP4155349A1 (de) 2021-09-24 2023-03-29 Becton, Dickinson and Company Wasserlösliche gelbe grünabsorbierende farbstoffe
WO2023215784A1 (en) 2022-05-04 2023-11-09 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784524A (en) * 1971-06-25 1974-01-08 Grace W R & Co Urethane/thioether-containing polyene composition and the reaction product thereof
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CH586739A5 (de) * 1973-10-17 1977-04-15 Hoechst Ag
US4134887A (en) * 1973-10-17 1979-01-16 Hoechst Aktiengesellschaft Phenyl-azo-phenyl dyestuffs
US4179387A (en) * 1974-03-12 1979-12-18 Fuji Photo Film Co., Ltd. Process for producing magnetic FE oxide
IL47468A (en) * 1975-06-12 1979-05-31 Rehovot Res Prod Process for the cross-linking of proteins using water soluble cross-linking agents
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE2607766C3 (de) * 1976-02-26 1978-12-07 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung von trägergebundenen biologisch aktiven Substanzen
US4228019A (en) * 1978-06-19 1980-10-14 Texaco Development Corp. Secondary recovery process
US4473693A (en) * 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
US4356166A (en) * 1978-12-08 1982-10-26 University Of Utah Time-release chemical delivery system
US4430260A (en) * 1979-02-27 1984-02-07 Lee Weng Y Penicillin-polyvinyl alcohol conjugate and process of preparation
US4296097A (en) * 1979-02-27 1981-10-20 Lee Weng Y Suppression of reaginic antibodies to drugs employing polyvinyl alcohol as carrier therefor
US4241199A (en) * 1979-09-18 1980-12-23 Union Carbide Corporation Novel polyester diols
US4280979A (en) * 1979-09-18 1981-07-28 Union Carbide Corporation Copolymers, compositions, and articles, and methods for making same
JPS585320A (ja) * 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
US4973493A (en) * 1982-09-29 1990-11-27 Bio-Metric Systems, Inc. Method of improving the biocompatibility of solid surfaces
JPS59204144A (ja) * 1983-04-12 1984-11-19 Daikin Ind Ltd 新規含フッ素化合物およびその製法
SE470099B (sv) * 1984-05-17 1993-11-08 Jerker Porath Sulfonaktiverade tioeteradsorbenter för separation av t ex protein
SE454885B (sv) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
US4616644A (en) * 1985-06-14 1986-10-14 Johnson & Johnson Products, Inc. Hemostatic adhesive bandage
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4883864A (en) * 1985-09-06 1989-11-28 Minnesota Mining And Manufacturing Company Modified collagen compound and method of preparation
US4983494A (en) * 1985-10-16 1991-01-08 Fuji Photo Film Co., Ltd. Image forming process including heating step
CA1283046C (en) * 1986-05-29 1991-04-16 Nandini Katre Tumor necrosis factor formulation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4871785A (en) * 1986-08-13 1989-10-03 Michael Froix Clouding-resistant contact lens compositions
DE3628717A1 (de) * 1986-08-23 1988-02-25 Agfa Gevaert Ag Haertungsmittel fuer proteine, eine damit gehaertete bindemittelschicht und eine solche schicht enthaltendes fotografisches aufzeichnungsmaterial
US4931544A (en) * 1986-09-04 1990-06-05 Cetus Corporation Succinylated interleukin-2 for pharmaceutical compositions
DE3634525A1 (de) * 1986-10-10 1988-04-21 Miles Lab Testmittel und indikatoren zum nachweis von thiolgruppen und verfahren zu deren herstellung
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NL8800577A (nl) * 1988-03-08 1989-10-02 Stichting Tech Wetenschapp Werkwijze voor het aanbrengen van een bloedcompatibele bekleding op polyetherurethaanvormstukken.
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
GB8824592D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Purification process
GB8824593D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
WO1990015628A1 (en) * 1989-06-14 1990-12-27 Cetus Corporation Polymer/antibiotic conjugate
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5171264A (en) * 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
JP3122460B2 (ja) * 1990-08-31 2001-01-09 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・ミネソタ 固相用途のためのポリエチレングリコール誘導体
US5380536A (en) * 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
SE467308B (sv) * 1990-10-22 1992-06-29 Berol Nobel Ab Fast yta belagd med ett hydrofilt ytterskikt med kovalent bundna biopolymerer, saett att framstaella en saadan yta och ett konjugat daerfoer
KR100234520B1 (ko) * 1991-01-18 1999-12-15 그레고리 아보트 종양괴사인자 매개병 치료용 의약품 조성물
EP0575545B1 (de) * 1991-03-15 2003-05-21 Amgen Inc. Pegylation von polypeptiden
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
DK52791D0 (da) * 1991-03-22 1991-03-22 Kem En Tec As Adsorptionsmatricer
DK130991D0 (da) * 1991-07-04 1991-07-04 Immunodex K S Polymere konjugater
DE69213240T2 (de) * 1991-07-04 1997-04-24 Immunodex K S Wasserlösliche reagenzien und konjugate auf polymerbasis, die vom divinylsulfon abgeleitete reste enthalten
US5414135A (en) 1991-12-30 1995-05-09 Sterling Winthrop Inc. Vinyl sulfone coupling of polyoxyalkylenes to proteins
EP0622394A1 (de) * 1993-04-30 1994-11-02 S.A. Laboratoires S.M.B. Umkehrbare Modifikation von Verbindungen, Schwefel enthaltend, mit Polyalkylengycol und ihre Verwendung

Also Published As

Publication number Publication date
AU1054895A (en) 1995-05-29
CA2176203A1 (en) 1995-05-18
RO118434B1 (ro) 2003-05-30
US6610281B2 (en) 2003-08-26
KR100225746B1 (ko) 1999-10-15
HU9601253D0 (en) 1996-07-29
EP1176160A3 (de) 2004-03-03
EE03448B1 (et) 2001-06-15
NO315377B1 (no) 2003-08-25
HU225649B1 (en) 2007-05-29
SK60896A3 (en) 1997-04-09
EP0728155B1 (de) 2002-04-03
ES2173943T3 (es) 2002-11-01
US5739208A (en) 1998-04-14
PL314298A1 (en) 1996-09-02
CZ137596A3 (en) 1996-10-16
NO961918D0 (no) 1996-05-10
UA58481C2 (uk) 2003-08-15
CN1137280A (zh) 1996-12-04
EE9600128A (et) 1997-04-15
BG100568A (bg) 1996-12-31
BG63399B1 (bg) 2001-12-29
FI962004A (fi) 1996-05-10
FI117441B (fi) 2006-10-13
FI962004A0 (fi) 1996-05-10
DK0728155T3 (da) 2002-07-29
RO121855B1 (ro) 2008-06-30
NO961918L (no) 1996-07-12
US5446090A (en) 1995-08-29
JPH09508926A (ja) 1997-09-09
EP1176160A2 (de) 2002-01-30
NZ276313A (en) 1997-04-24
PL180149B1 (pl) 2000-12-29
US20050209416A1 (en) 2005-09-22
US6894025B2 (en) 2005-05-17
US7214366B2 (en) 2007-05-08
SK284527B6 (sk) 2005-05-05
EP0728155A1 (de) 1996-08-28
US20020150548A1 (en) 2002-10-17
HK1042312A1 (zh) 2002-08-09
US5900461A (en) 1999-05-04
HUP9601253A2 (en) 2001-06-28
US20040037801A1 (en) 2004-02-26
CZ295640B6 (cs) 2005-09-14
CN1085689C (zh) 2002-05-29
AU687937B2 (en) 1998-03-05
ATE215577T1 (de) 2002-04-15
BR9408048A (pt) 1996-12-24
WO1995013312A1 (en) 1995-05-18
KR960705869A (ko) 1996-11-08
RU2176253C2 (ru) 2001-11-27
DE69430317T2 (de) 2002-10-02
CA2176203C (en) 2003-06-10
JP3114998B2 (ja) 2000-12-04

Similar Documents

Publication Publication Date Title
DE69430317D1 (de) Wasserlösliche aktive sulfone von polyethylenglycolen
CA2174325A1 (en) Non-antigenic branched polymer conjugates
CA2323048A1 (en) Poly(ethylene glycol) derivatives with proximal reactive groups
CA2283939A1 (en) Non-antigenic branched polymer conjugates
DE68906366T2 (de) CD4-Polypeptidderivate.
FR2710843B1 (fr) Composition d'organopolysiloxane d'aspect gélifié, sans gélifiant, utilisable en cosmétique et dermatologie.
MX9100448A (es) Clatratos de peroxiacidos
ATE116135T1 (de) Einschlusskomplex von nimesulide mit cyclodextrinen.
DE69027558T2 (de) Landwirtschaftliche Schaum-Zusammensetzungen
MX9101393A (es) Uso de marcadores moleculares en la reproduccion de arboles
DE3853547D1 (de) Reversibel ausfällbare, wasserlösliche Polymerkonjugate, ihre Herstellung und Verwendung in der homogenen Katalyse.
ITTO920282A0 (it) Composizione polimerica amidacea biodegradabile.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NEKTAR THERAPEUTICS AL,CORP., HUNTSVILLE, ALA., US

R082 Change of representative

Ref document number: 728155

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE

R081 Change of applicant/patentee

Ref document number: 728155

Country of ref document: EP

Owner name: NEKTAR THERAPEUTICS, US

Free format text: FORMER OWNER: NEKTAR THERAPEUTICS AL,CORP., HUNTSVILLE, US

Effective date: 20121113

R082 Change of representative

Ref document number: 728155

Country of ref document: EP

Representative=s name: VON KREISLER SELTING WERNER, DE

Effective date: 20121113